Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes
The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.
Authors
- Shinje Moon (ORCID: https://orcid.org/0000-0003-3298-3630)
- Hangyul Song
- Cheol-Young Park
- Chang‐Myung Oh (ORCID: https://orcid.org/0000-0001-6681-4478)
- Kyungdo Han (ORCID: https://orcid.org/0000-0002-6096-1263)
- Sungsoo Cho (ORCID: https://orcid.org/0000-0003-2059-1584)
- Jiwon Park (ORCID: https://orcid.org/0000-0002-4972-0397)
- Yumin Kim
- Sung Woo Cho (ORCID: https://orcid.org/0000-0003-3983-817X)
Institutions
- Soongsil University (KR)
- Yonsei University (KR)
- Gwangju Institute of Science and Technology (KR)
- Kangbuk Samsung Hospital (KR)
- Inje University Ilsan Paik Hospital (KR)
- Gangnam Severance Hospital (KR)
- Hanyang University (KR)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1186/s12933-024-02417-6
- Citations
- 13
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Daewoong Pharmaceutical Company
- National Research Council of Science and Technology
- Ministry of Science and ICT, South Korea